Does GLP-1 therapy cause muscle loss? What the research actually says.

What the studies found

The STEP trials (the clinical basis for semaglutide's approval) showed significant total weight loss — up to 15% of body weight over 68 weeks. What the trial data also showed, and what gets less attention, is that lean mass loss was substantial alongside fat mass loss.

Analysis of body composition data from GLP-1 trials has found that approximately 25–40% of total weight lost can come from lean mass rather than fat, depending on baseline body composition, physical activity, and — critically — protein intake. For someone who loses 40 pounds, that could mean 10–16 pounds of muscle lost alongside the fat.

Why GLP-1 makes the problem worse

On a conventional calorie-restricted diet, people typically reduce food intake gradually and consciously. They can make intentional choices to prioritize protein-rich foods. On GLP-1 therapy, appetite suppression can be severe and fast — it's not uncommon to go from eating normally to having almost no appetite within the first few weeks of dose escalation.

The result is that the protein gap opens quickly and stays open. Clinical guidelines recommend 1.2–1.6g of protein per kilogram of body weight during active weight loss to preserve lean mass. Someone eating one or two small meals a day is rarely hitting that — often getting 40–60g of protein when they need 100g or more.

The metabolic consequence of muscle loss

Losing lean mass during weight loss has two major downstream effects:

• Lower resting metabolic rate. Muscle burns calories at rest. Less muscle means your body requires fewer calories at baseline, making weight regain after stopping therapy significantly more likely.
• Body composition outcomes. Many people who lose weight on GLP-1 therapy and then stop report that they look "deflated" rather than lean — a symptom of fat loss alongside muscle loss, sometimes called the "Ozempic face" or "Ozempic body" effect in media coverage. The underlying mechanism is inadequate protein and lean mass preservation.

What actually prevents muscle loss on GLP-1

The research points to three interventions that independently and additively reduce lean mass loss during weight loss:

• Adequate protein intake (1.2–1.6g/kg/day) — the most impactful single variable
• Resistance exercise — 2–3 sessions per week of progressive overload
• Creatine supplementation — 3–5g/day maintenance dose supports muscle cell hydration and strength output, which preserves lean mass signals

Most people on GLP-1 therapy can realistically address all three. The protein and creatine gaps can be closed with supplementation when appetite makes food-based intake insufficient.